Clinical trials: Manic State
Bipolar Disorder
Taurine in Adolescents With Bipolar Disorder
Recently, McLean hospital conducted a 4 month taurine study which showed a reduction in mania ratings. As a follow-up to the preliminary taurine study, and complementary to the currently ongoing double-blind, placebo-controlled…
- Trial name
- NCT00391001
- Testing
- Taurine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Cambridge Health Alliance
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Disorder With Hyperactivity
Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood
This study will evaluate the effectiveness of an integrative group psychosocial therapy combined with stimulant medication in treating children with attention deficit hyperactivity disorder plus impairments in mood.
- Trial name
- NCT00632619
- Testing
- Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Florida International University
Bipolar Disorder
Decision-Making in Bipolar Disorder
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study.
- Trial name
- NCT01463111
- Testing
- Lithium, Valproate, Lamotrigine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Emory University
Bipolar Depression
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
- Trial name
- NCT00322764
- Testing
- Uridine
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Repligen Corporation
Bipolar Disorder
3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159744
- Testing
- Asenapine, Olanzapine
- Volunteers
- 488 people
- Sponsor
- Organon and Co
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Bipolar Disorder
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT00257166
- Testing
- Ziprasidone oral capsules
- Where
- 50 sites in United States
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Manic
Magnetic Seizure Therapy for Bipolar Mania
This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety for bipolar mania. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy…
- Trial name
- NCT03160664
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System, treatment as usual (TAU)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Mental Health Center
Bipolar Disorder
Aripiprazole in Patients With Acute Mania
The purpose of this trial is to test the safety \& efficacy of aripiprazole in patients with Bipolar Mania for a period of at least 12 weeks.
- Trial name
- NCT00095511
- Testing
- aripiprazole
- Where
- 38 sites in United States
- Volunteers
- 615 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Bipolar Disorder (BD)
Anticipating Depressive and Manic Episodes in Bipolar Disorders Using Vocal Biomarkers
Bipolar disorder (BD) is a chronic, cyclical mental illness affecting over 1% of the global population. It is characterized by alternating episodes of elevated mood and energy (mania or hypomania) and episodes of decreased mood…
- Trial name
- SPEECHBIPO (NCT07298278)
- Testing
- Voice interviews and questionnaires carried out via the CALLYOPE application, Sleep measurements using an under-mattress sensor, Smartwatch for measuring activity, sleep, and skin temperature
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier St Anne
Bipolar Disorder
Clinical Trial of Mifepristone for Bipolar Depression
Bipolar Depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness.
- Trial name
- NCT00043654
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Bipolar Disorder, Schizophrenia
Treatment of Mania Symptoms With Drug Therapy
This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
- Trial name
- NCT00183443
- Testing
- Divalproex-extended release (DVP-ER), Lithium, Quetiapine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Palo Alto Veterans Institute for Research
Bipolar Disorder, Manic
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462586
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 354 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during a long-term open label study in children and adolescents (ages 10-17) with Bipolar I Disorder (Manic or Mixed).
- Trial name
- NCT01124877
- Testing
- ziprasidone oral capsules
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
The primary objective of this trial was to characterize the long-term (up to 40 weeks) safety and tolerability of asenapine in bipolar I disorder subjects who had not completely responded to continuing treatment with lithium or…
- Trial name
- NCT00145509
- Testing
- Asenapine
- Volunteers
- 77 people
- Sponsor
- Organon and Co